Merck Diabetes Drug Cuts Blood Sugar
Posted on: Wednesday, 6 December 2006, 21:00 CST
New research analyzing Merck & Co.'s Janumet has revealed that it provides substantial reductions in blood sugar levels in type 2 diabetes patients.
Janumet is an investigational combination therapy of sitagliptin phosphate plus metformin. Janumet is designed to provide an additional treatment option for patients who need more than one oral agent to help control their blood sugar.
In the study, patients had an average blood glucose level of 287 milligrams per milliliter two hours after eating, and 197 milligrams per milliliter on an empty stomach.
"Typically, oral medications for type 2 diabetes principally either reduce post-meal glucose levels or reduce fasting blood glucose levels. These study data are important because they showed substantial reductions in both measures of blood glucose levels," said John Amatruda, vice president, clinical research, Merck & Co.
Janumet is currently under review by the FDA and Merck expects action on the new drug application by the end of March 2007. The company said it is also moving forward as planned with regulatory filings in countries outside the US.
Source: Datamonitor
Related Articles
- Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients?
- Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
- Blood Levels of Paliperidone Extended-Release Tablets Are Not Increased By Common Antidepressant
- Isis Pharmaceuticals Reports Positive Phase 2 Data: ISIS 113715 Improves Glucose Control in Patients With Type 2 Diabetes
- BYETTA(R) Shown to Reduce Blood Glucose Levels When Added to Patients Using a TZD
- The Merck Patient Assistance Program Remains an Option for Many Medicare Beneficiaries
- Serum Neopterin Levels in HIV Infected Patients With & Without Tuberculosis
- Effects of Metformin and Rosiglitazone Treatment on Insulin Signaling and Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Study
- Malondialdehyde, Glutathione, Glutathione Peroxidase and Homocysteine Levels in Type 2 Diabetic Patients With and Without Microalbuminuria
- OSI Pharmaceuticals Presents Data on the Impact of Smoking on the Blood Levels of Tarceva at the 96th Annual Meeting of the AACR
 |
 |
User Comments (0)
RSS Feeds